New Hope for Vision: FDA Approves Eydenzelt, a Biosimilar for Age-Related Macular Degeneration and Diabetic Retinopathy
The landscape of retinal disease treatment has expanded with the FDA approval of Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea (aflibercept). This approval marks a important step toward increasing access to vital therapies for conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR). Let’s explore what this means for you and your vision health.
What is Eydenzelt and Why Does it Matter?
Eydenzelt offers a comparable treatment option to Eylea, a well-established medication used to treat several retinal diseases. Biosimilars are highly similar to existing biologic drugs,offering the same safety and effectiveness at a perhaps lower cost. This increased affordability can substantially impact access to care for the millions affected by vision-threatening conditions.
Recent clinical trials demonstrated eydenzelt’s equivalence to Eylea, showing similar results in efficacy, safety, and immunogenicity. Specifically,the study,identified as NCT04739306,evaluated the biosimilar’s performance up to week 8 from baseline,meeting all predefined equivalence criteria.
Understanding Age-Related Macular Degeneration (AMD)
AMD is a leading cause of vision loss for Americans aged 50 and older. It affects central vision, making it difficult to perform everyday tasks like reading or driving.While complete blindness is uncommon, the impact on quality of life can be substantial.
Here’s a breakdown of key points about AMD:
* Risk Factors: Age, smoking, high blood pressure, and a diet high in saturated fat increase your risk.
* Dry AMD: The more common form, typically progresses slowly.
* Wet AMD (wAMD): A less common, but more aggressive form, characterized by abnormal blood vessel growth under the retina. This leakage causes rapid vision loss.
* Symptoms: Blurry vision, difficulty recognizing faces, wavy lines, and a central blind spot are common warning signs.
currently, there’s no cure for AMD, but treatments can help slow its progression and preserve your vision. As stated by Brown in a recent press release, “Advanced AMD is a leading cause of irreversible blindness and visual impairment in the world, and nearly 20 million people in the US are living with some form of AMD.”
Retinal Diseases: Beyond AMD
AMD isn’t the only retinal condition impacting vision. Other diseases, like diabetic macular edema (DME) and diabetic retinopathy (DR), can also lead to significant vision impairment.
These conditions, frequently enough linked to diabetes, cause blood vessels in the retina to weaken and leak fluid. This leads to:
* Swelling in the retina.
* Blurred or distorted vision.
Early detection and treatment are crucial for managing these conditions and protecting your sight.
The Importance of Timely Access to Treatment
The approval of Eydenzelt underscores the importance of accessible and affordable treatments for retinal diseases. As Jacob-Nara emphasized,”Timely access to effective therapies is essential for individuals affected by retinal diseases. We are proud to have Eydenzelt approved by the FDA,and we look forward to expanding the availability and access of biological treatments across the US.”
If you are experiencing any changes in your vision, it’s vital to consult with a qualified ophthalmologist or retina specialist immediately. Early diagnosis and intervention can make a significant difference in preserving your vision and maintaining your quality of life.
References:
- Celltrion. (2025, October 10). Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept). news release. https://www.celltrion.com/en-us/company/media-center/press-release/4201
- ClinicalTrials.gov. (2023, December 5). Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema. NCT04739306. https://clinicaltrials.gov/study/NCT04739